Investors

Investors

Corporate Profile

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of Europe.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its recently opened GMP manufacturing site in Princeton, New Jersey, USA.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of

More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI
ERYTECH Announces P resentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI Interim results from the Phase 1 rESPECT trial of eryaspase plus mFOLFIRINOX as first-line treatment for advanced pancreatic cancer patients , presented in a poster presentation, confirm
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2021
                Monthly information related to total number of voting rights and shares composing the share capital – December 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary ERYTECH to Participate in the Upcoming January Virtual Investor Conferences
ERYTECH to Participate in the Upcoming January Virtual Investor Conferences Cambridge, MA (U.S.) and Lyon (France), January 3 , 202 2 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary ERYTECH Announces $7.85 Million Registered Direct Offering
ERYTECH Announces $ 7.85 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), December 14 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext:   ERYP) (the “Company”) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Mar 11, 2022

Business Update and Financial Highlights for the Fourth Quarter and Full Year 2021 (after U.S. market close)

Summary Toggle Mar 14, 2022 at 8:30 AM EDT

Erytech Pharma 4th Quarter and Full Year of 2021 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Top